GLP-1 pathway
Semaglutide Wegovy®
May help eligible adults reduce excess body weight and maintain weight reduction when paired with nutrition, activity, and ongoing medical care.
Medical review required FDA label contextJM Wellness Body Composition Studio
Educational visualization Entries stay in this tab
Live surface
Watch the reference respond.
Height changes stature and how the same weight is distributed. Weight and muscularity select the closest sharp body reference. Waist moves the measurement line only.
HeightChanges stature and weight relative to height.
Weight + buildSelect the closest full-body reference for that height.
WaistMoves the waist cue without deforming the head or backdrop.
Inside guide
Where visceral fat can sit.
The organs stay fixed. The amber emphasis responds to your screening inputs and marks a typical abdominal region—not measured tissue.
Visceral adipose depotsOmental, mesenteric, retroperitoneal and perirenal regions.
Subcutaneous adiposeLocated beneath the skin, outside the abdominal cavity.
Screening emphasisChanges with the estimate; it is not drawn as your tissue.
Primary central-adiposity screen
iWaist ÷ height is less distorted by muscularity than BMI. It is still a screen—not a visceral-fat measurement.
0.50Increased range
Increased central-adiposity range
Height–weight index (secondary BMI reference)
30.4Not a diagnosis
This number can overstate body fat in muscular people. It never labels or shapes this body. 
Live body matchSharp reference—no image stretching
Chosen direction
See the numbers you chose—not a treatment promise.
Now200 lb · 34 in
→Your direction175 lb · 31 in
What this estimate can inform
A better conversation about medical weight care.
Your entries can help frame a clinician conversation. They do not select a medication or determine eligibility.
GIP + GLP-1 pathway
Tirzepatide Zepbound®
May help eligible adults reduce excess body weight and maintain weight reduction as part of a clinician-guided plan with nutrition and activity.
Medical review required FDA label contextSpecific abdominal-fat indication
Tesamorelin Egrifta WR®
FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is weight-neutral and is not a general weight-loss treatment.
Specific indication only FDA label contextThis visual estimate cannot assess medical history, weight-related conditions, contraindications, pregnancy, medication interactions, labs, or whether a prescription is appropriate. Other GH-releasing or research peptides are not selected from an image; ask a licensed provider about evidence, approval status, and safety.
The next useful number
Confirm with a measured baseline.
A SECA assessment can add a professional body-composition baseline. A JM provider can interpret it with your history, exam, labs, and goals.
For adults 20+. Not for pregnancy. Educational screening only. This illustration is not CT, medical imaging, a scan, personalized anatomy, a diagnosis, or a treatment forecast. Entries stay in this browser tab and are not saved.